Benzodiazepines have been used as surgical premedication for decades, valued for their anxiolytic, sedative, and amnestic properties. Among the agents studied—diazepam, midazolam, lorazepam, and flunitrazepam—considerable differences exist in the onset, depth, and duration of anterograde amnesia they produce. These differences have meaningful clinical implications for the perioperative management of surgical patients, particularly in the use of benzodiazepines for surgical amnesia.
The amnestic effect of benzodiazepines is anterograde in nature: it impairs the acquisition and consolidation of new information without affecting recall of events that preceded drug administration. The mechanism is primarily attributable to reduced attention and rehearsal, secondary to sedation, and is mediated through GABA-A receptor occupancy.
A critical point for anesthesia providers to understand is that the onset and duration of amnesia are determined not by plasma elimination half-life but by the rate of receptor association and dissociation. As a result, lorazepam, which has a relatively short half-life, produces a delayed onset of amnesia at approximately two hours after intravenous administration and a prolonged amnestic window of four to six hours or more, while intravenous diazepam and midazolam reach peak amnestic effect within two minutes and last only 30–60 minutes¹.
The clinical superiority of midazolam over diazepam for surgical amnesia has been demonstrated by comparitive studies of benzodiazepines. In a randomized double-blind trial comparing intramuscular midazolam (0.1 mg/kg), diazepam (0.2 mg/kg), and placebo in 76 male patients undergoing urological procedures under spinal anesthesia, more than 90% of patients in the midazolam group demonstrated total or partial anterograde amnesia for induction room and operative theatre events, compared with zero patients in either the diazepam or placebo groups.
The sedative and anxiolytic effects of midazolam were evident within 5–10 minutes, reached maximum effect between 30 and 90 minutes, and were followed by rapid recovery—a pharmacokinetic profile ideally suited to the perioperative timeline. Diazepam, by contrast, showed negligible sleep-inducing effect and no significant anxiolysis during the first 60 minutes, the period of greatest patient stress, rendering it practically equivalent to placebo during the most clinically relevant window². Midazolam’s water-solubility facilitates superior intramuscular absorption compared with diazepam, which is dissolved in propylene glycol and exhibits substantially delayed uptake by this route.
Though closely linked, the relationship between sedation and amnesia is not perfectly correlated. While the same GABA-A receptors are implicated in both effects, as indicated by the equal antagonism of both by flumazenil, differences in receptor occupancy rates, drug potency, and individual pharmacokinetic variability mean that amnesia may persist independently of clinically apparent sedation, and vice versa¹. This dissociation carries important implications: patients appearing alert may nonetheless be amnestic, while strongly sedated patients may retain some recall.
At the population level, the amnestic properties of perioperative benzodiazepines make them valuable in the prevention of intraoperative awareness. A systematic review and meta-analysis of 34 randomized controlled trials found that perioperative benzodiazepine use significantly decreased the risk of intraoperative awareness (risk ratio 0.26; 95% CI 0.12–0.58), though the quality of evidence was low. The same review found no statistically significant increase in postoperative delirium attributable to benzodiazepines when compared with placebo or other agents, with the exception of comparisons to dexmedetomidine, where benzodiazepines were associated with an 83% greater risk of delirium³.
Due to its rapid onset, superior amnestic efficacy via both intravenous and intramuscular routes, and predictable recovery profile, midazolam remains the benzodiazepine of choice for surgical amnesia. Lorazepam offers a prolonged amnestic window suited to extended procedures, while diazepam’s poor intramuscular absorption and delayed action limit its utility as surgical premedication. Clinicians must weigh the established amnestic benefits of these agents against the evolving evidence on postoperative cognitive outcomes, particularly in elderly and high-risk populations.
References
- King, D. J. Benzodiazepines, amnesia and sedation: theoretical and clinical issues and controversies. Hum. Psychopharmacol. 7, 79–87 (1992). https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.470070202
- Reinhart, K., Dallinger-Stiller, G., Dennhardt, R., Heinemeyer, G. & Eyrich, K. Comparison of midazolam, diazepam and placebo i.m. as premedication for regional anaesthesia: a randomized double-blind study. Br. J. Anaesth. 57, 294–299 (1985). https://pubmed.ncbi.nlm.nih.gov/3156614/
- Wang, E. et al. Effect of perioperative benzodiazepine use on intraoperative awareness and postoperative delirium: a systematic review and meta-analysis of randomised controlled trials and observational studies. Br. J. Anaesth.131, 302–313 (2023). https://doi.org/10.1016/j.bja.2022.12.001
